Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We compared the efficacy of high-dose cytarabine alone to that of intermediate-dose cytarabine combined with anthracyclines as consolidation therapy. Patients enrolled in the Korea University acute myeloid leukemia (AML) registry received remission induction chemotherapy with the same standard induction regimen (idarubicin and cytarabine 3 + 7). Postremission therapy was performed for three or four cycles according to one of the following regimens: high-dose cytarabine (3 g/m<sup>2</sup>) or combination of intermediate-dose cytarabine (1 g/m<sup>2</sup>) with anthracyclines (idarubicin or mitoxantrone). Among the 443 AML patients enrolled in the registry, 145 patients received consolidation chemotherapy. The median overall survival (OS) and relapse-free survival (RFS) in the high-dose cytarabine group were significantly longer than those in the anthracycline combination group (OS, not reached vs. 16.6 months, p = 0.045; RFS, 38.6 months vs. 11.0 months, p = 0.011). The median duration of neutropenia was longer in the anthracycline combination group than in the high-dose cytarabine group (8 vs. 10 days, p = 0.001). This study suggests that high-dose cytarabine consolidation may produce superior outcomes than combination treatment with intermediate-dose cytarabine and anthracyclines and that the addition of anthracyclines during AML consolidation has limited value as compared to cytarabine intensification.

Original languageEnglish
Pages (from-to)1485-1492
Number of pages8
JournalAnnals of Hematology
Volume94
Issue number9
DOIs
Publication statusPublished - 2015 May 6

Keywords

  • Acute myeloid leukemia
  • Anthracyclines
  • Consolidation chemotherapy
  • High-dose cytarabine

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines'. Together they form a unique fingerprint.

  • Cite this